Creatinine-cystatin C Ratio and Mortality in Cancer Patients: a Retrospective Cohort Study

Overview

Journal J Cachexia Sarcopenia Muscle

Date 2022 Apr 28

PMID 35478277

Authors

Chan-Young Jung

Hyung Woo Kim

Seung Hyeok Han

Tae-Hyun Yoo

Shin-Wook Kang

Jung Tak Park

Affiliations

Soon will be listed here.

Abstract

Background: Muscle wasting is prevalent in cancer patients, and early recognition of this phenomenon is important for risk stratification. Recent studies have suggested that the creatinine-cystatin C ratio may correlate with muscle mass in several patient populations. The association between creatinine-cystatin C ratio and survival was assessed in cancer patients.

Methods: A total of 3060 patients who were evaluated for serum creatinine and cystatin C levels at the time of cancer diagnosis were included. The primary outcome was 6-month mortality. The 1-year mortality, and length of intensive care unit (ICU) and hospital stay were also evaluated.

Results: The mean age was 61.6 ± 13.5 years, and 1409 patients (46.0%) were female. The median creatinine and cystatin C levels were 0.9 (interquartile range [IQR], 0.6-1.3) mg/dL and 1.0 (IQR, 0.8-1.5) mg/L, respectively, with a creatinine-cystatin C ratio range of 0.12-12.54. In the Cox proportional hazards analysis, an increase in the creatinine-cystatin C ratio was associated with a significant decrease in the 6-month mortality (per 1 creatinine-cystatin C ratio, hazard ratio [HR] 0.35; 95% confidence interval [CI], 0.28-0.44). When stratified into quartiles, the risk of 6-month mortality was significantly lower in the highest quartile (HR 0.30; 95% CI, 0.24-0.37) than in the lowest quartile. Analysis of 1-year mortality outcomes revealed similar findings. These associations were independent of confounding factors. The highest quartile was also associated with shorter lengths of ICU and hospital stay (both P < 0.001).

Conclusions: The creatinine-cystatin C ratio at the time of cancer diagnosis significantly associates with survival and hospitalization in cancer patients.

Citing Articles

Establishing discordance rate of estimated glomerular filtration rate between serum creatinine-based calculations and cystatin-C-based calculations in critically ill patients.

Williams V, Gerlach A Pharmacotherapy. 2025; 45(3):161-168.

PMID: 39945448 PMC: 11905338. DOI: 10.1002/phar.70000.

Low albumin-to-creatinine ratios (ACR) are associated with poor outcomes in cancer patients.

Zhao H, Li X, Liu X, Liu C, Zheng X, Chen Y BMC Cancer. 2025; 25(1):168.

PMID: 39875826 PMC: 11776132. DOI: 10.1186/s12885-025-13480-x.

The association of RBP4 with chronic kidney diseases in southern Chinese population.

Chen T, Liu Y, Wu S, Long S, Feng L, Lu W Front Endocrinol (Lausanne). 2024; 15:1381060.

PMID: 39698033 PMC: 11652128. DOI: 10.3389/fendo.2024.1381060.

Utilizing machine learning approaches to investigate the relationship between cystatin C and serious complications in esophageal cancer patients after esophagectomy.

Huo Z, Chong F, Luo S, Tong N, Lu Z, Zhang M Support Care Cancer. 2024; 33(1):31.

PMID: 39680175 DOI: 10.1007/s00520-024-09060-7.

Serum creatinine- and cystatin C-based indices are associated with the risk of subsequent sarcopenia: evidence from the China Health and Retirement Longitudinal Study.

Ning X, Xie C, Kong Y Front Nutr. 2024; 11:1471068.

PMID: 39634549 PMC: 11614666. DOI: 10.3389/fnut.2024.1471068.

References

Herou E, Dardashti A, Nozohoor S, Zindovic I, Ederoth P, Grubb A . The mortality increase in cardiac surgery patients associated with shrunken pore syndrome correlates with the eGFR/eGFR-ratio. Scand J Clin Lab Invest. 2019; 79(3):167-173. DOI: 10.1080/00365513.2019.1576101. View

Jung C, Joo Y, Kim H, Han S, Yoo T, Kang S . Creatinine-Cystatin C Ratio and Mortality in Patients Receiving Intensive Care and Continuous Kidney Replacement Therapy: A Retrospective Cohort Study. Am J Kidney Dis. 2020; 77(4):509-516.e1. DOI: 10.1053/j.ajkd.2020.08.014. View

Aversa Z, Costelli P, Muscaritoli M . Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther Adv Med Oncol. 2017; 9(5):369-382. PMC: 5424865. DOI: 10.1177/1758834017698643. View

von Haehling S, Coats A, Anker S . Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. J Cachexia Sarcopenia Muscle. 2021; 12(6):2259-2261. PMC: 8718061. DOI: 10.1002/jcsm.12899. View

Laird B, Kaasa S, McMillan D, Fallon M, Hjermstad M, Fayers P . Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013; 19(19):5456-64. DOI: 10.1158/1078-0432.CCR-13-1066. View

Schmidt S, Rohm M, Herzig S, Diaz M . Cancer Cachexia: More Than Skeletal Muscle Wasting. Trends Cancer. 2018; 4(12):849-860. DOI: 10.1016/j.trecan.2018.10.001. View

Mador M . Muscle mass, not body weight, predicts outcome in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166(6):787-9. DOI: 10.1164/rccm.2206003. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

Simonsen C, Heer P, Bjerre E, Suetta C, Hojman P, Pedersen B . Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical Oncology: A Meta-analysis. Ann Surg. 2018; 268(1):58-69. DOI: 10.1097/SLA.0000000000002679. View

10.

Roeland E, Bohlke K, Baracos V, Bruera E, Del Fabbro E, Dixon S . Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol. 2020; 38(21):2438-2453. DOI: 10.1200/JCO.20.00611. View

11.

Prado C, Lieffers J, McCargar L, Reiman T, Sawyer M, Martin L . Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9(7):629-35. DOI: 10.1016/S1470-2045(08)70153-0. View

12.

Fearon K, Arends J, Baracos V . Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2012; 10(2):90-9. DOI: 10.1038/nrclinonc.2012.209. View

13.

Ulmann G, Kai J, Durand J, Neveux N, Jouinot A, De Bandt J . Creatinine-to-cystatin C ratio and bioelectrical impedance analysis for the assessement of low lean body mass in cancer patients: Comparison to L3-computed tomography scan. Nutrition. 2020; 81:110895. DOI: 10.1016/j.nut.2020.110895. View

14.

Knight E, Verhave J, Spiegelman D, Hillege H, de Zeeuw D, Curhan G . Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004; 65(4):1416-21. DOI: 10.1111/j.1523-1755.2004.00517.x. View

15.

Baracos V . Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr. 2006; 26:435-61. DOI: 10.1146/annurev.nutr.26.061505.111151. View

16.

Wang S, Xie L, Xu J, Hu Y, Wu Y, Lin Z . Predictive value of serum creatinine/cystatin C in neurocritically ill patients. Brain Behav. 2019; 9(12):e01462. PMC: 6908890. DOI: 10.1002/brb3.1462. View

17.

Kwon W, Kim T, Nahm C, Moon Y, Kim J . Aberrant cystatin-C expression in blood from patients with breast cancer is a suitable marker for monitoring tumor burden. Oncol Lett. 2018; 16(5):5583-5590. PMC: 6176264. DOI: 10.3892/ol.2018.9380. View

18.

Barreto E, Poyant J, Coville H, Dierkhising R, Kennedy C, Gajic O . Validation of the sarcopenia index to assess muscle mass in the critically ill: A novel application of kidney function markers. Clin Nutr. 2018; 38(3):1362-1367. DOI: 10.1016/j.clnu.2018.05.031. View

19.

Jiang Y, Zhang J, Zhang C, Hong L, Jiang Y, Lu L . The role of cystatin C as a proteasome inhibitor in multiple myeloma. Hematology. 2020; 25(1):457-463. DOI: 10.1080/16078454.2020.1850973. View

20.

Vaughan V, Martin P, Lewandowski P . Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle. 2012; 4(2):95-109. PMC: 3684701. DOI: 10.1007/s13539-012-0087-1. View